Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[The tools for the governance of mutational oncology and agnostic drugs: from place in therapy to place in pathway.]

Recenti progressi in medicina - 1 Dec 2021

Martini Nello, Piccinni Carlo

Abstract excerpt

In the oncology, the construction, implementation and evaluation of the care pathway must consider the integration of the "histological approach" with the "mutational" one, focused on the identification of specific molecular alterations to which the so-called "agnostic drugs" are targeted. To investigate this issue, a specific Working Group of the MaCroScopio Project (observatory on chronicity) was held in which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Italy
Share to Medical Oncology
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Precision Medicine

Source

Identifiers

PMID: 34924576
DOI: 10.1701/3710.37004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

[The tools for the governance of mutational oncology and agnostic drugs: from place in therapy to place in pathway.]PMID 34924576Read ↗

[The regulatory evaluation of tumor-agnostic drugs.]Semantic proximity Read ↗

Do more targets allow more cancer treatments, or not?Semantic proximity Read ↗

[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.]Semantic proximity Read ↗

The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific SocietiesSemantic proximity Read ↗

The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of GermanySemantic proximity Read ↗

The organization of clinical trials for oncology at IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" Napoli and the impact of the OECI accreditation process.Semantic proximity Read ↗

Genomic expertise in action: molecular tumour boards and decision‐making in precision oncologySemantic proximity Read ↗

Modelling the HPRT-gene mutation induction of particle beams: systematicin vitrodata collection, analysis and microdosimetric kinetic model implementation.Semantic proximity Read ↗

The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary qualitySemantic proximity Read ↗

Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.